Recobinant human proinsulin C peptide (Shanghai Newsummit/Shanghai Yizhong)
重组人胰岛素原C肽 (上海新生源/上海益众生物)
Report date: 2025/04/07 15:07:08
Base Information
Drug NameRecobinant human proinsulin C peptide (Shanghai Newsummit/Shanghai Yizhong)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Xinshengyuan Biological Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesN/A
Inactive CompaniesShanghai Sisheng Enterprise Management Consulting Co LtdShanghai Yizhong Bio-Technology Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A